The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-U.S. yields hit new peaks, stocks drop with Fed at hand

Wed, 17th Mar 2021 15:01

* Investors watching for signs of faster policy
normalization

* Fed statement due at 1400 EDT/1800 GMT

* Russian rouble hit by Biden comments on Putin

* MSCI global share gauge down, tech stocks weaker
(Updates with opening of U.S. markets, changes dateline from
London)

By Lewis Krauskopf

NEW YORK, March 17 (Reuters) - Benchmark U.S. Treasury
yields hit a fresh 13-month high and a gauge of global stocks
dropped on Wednesday as investors awaited the highly anticipated
outcome of the latest Federal Reserve meeting.

The Russian rouble weakened by more than 1% after U.S.
President Joe Biden said his Russian counterpart Vladimir Putin
will "pay a price" for directing efforts to meddle in the 2020
U.S. presidential election.

Fed policymakers are expected to forecast that the U.S.
economy will grow in 2021 at the fastest rate in decades as
COVID-19 vaccinations rise and a $1.9 trillion relief package
aids households.

Ahead of the Fed statement expected at 1400 EDT/1800 GMT,
the yield on the benchmark U.S. Treasury note rose to 1.676%.

"This is one of the most important Fed meetings we've had
for some time and the impact will be felt across asset classes,"
said Seema Shah, chief strategist at Principal Global Investors.

"Markets are hoping for reassurance from the Fed that rising
bond yields are not something to worry about, and that takes a
bit of steam out of the bond market."

On Wall Street, the rise in bond yields continued to
pressure stocks, including tech and growth shares.

The Dow Jones Industrial Average rose 7.85 points, or
0.02%, to 32,833.8, the S&P 500 lost 16.06 points, or
0.41%, to 3,946.65 and the tech-heavy Nasdaq Composite
dropped 96.22 points, or 0.71%, to 13,375.35.

"Market is of the view that the 10-year yield could be
higher and if the Fed signals anything that matches that view,
we could see yields jump past the 2% mark," said Arthur Weise,
chief investment officer at Kingsland Growth Advisors.

The pan-European STOXX 600 index lost 0.51% and
MSCI's gauge of stocks across the globe shed
0.43%.

Benchmark 10-year notes last fell 8/32 in price
to yield 1.6497%, from 1.623% late on Tuesday.

In currencies trading, the dollar index rose 0.002%,
with the euro up 0.09% to $1.1911.

The sell-off in the rouble intensified after Biden was
quoted by ABC News as saying that Putin will face consequences
for directing efforts to swing last year's U.S. election in
Donald Trump's favor.

"There will be more sanctions coming, that is clear. The
question is how severe?" said North Asset Management's Peter
Kisler.

Oil slipped for a fourth day as concerns about weaker demand
in Europe outweighed an industry report that showed U.S. crude
inventories unexpectedly fell last week.

U.S. crude recently fell 0.52% to $64.46 per barrel
and Brent was at $67.93, down 0.67% on the day.

(Additionl reporting by Shashank Nayar and Medha Singh in
Bengaluru, Dhara Ranasinghe in London; Editing by Catherine
Evans and Elaine Hardcastle)

More News
Today 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.